Recent Investment Analysts’ Ratings Updates for Olema Pharmaceuticals (OLMA)

Several analysts have recently updated their ratings and price targets for Olema Pharmaceuticals (NASDAQ: OLMA):

• 12/12/2025 – Olema Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Olema Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – Olema Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Olema Pharmaceuticals had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a “buy” rating on the stock.
• 11/21/2025 – Olema Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $22.00 to $45.00. They now have an “outperform” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at HC Wainwright from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $29.00 to $32.00. They now have an “overweight” rating on the stock.

Insider Transactions at Olema Pharmaceuticals

In other news, Director Ian T. Clark sold 264,800 shares of Olema Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $29.73, for a total value of $7,872,504.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David C. Myles sold 51,000 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the completion of the sale, the insider directly owned 551,881 shares in the company, valued at approximately $16,810,295.26. This represents a 8.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 585,309 shares of company stock valued at $16,956,383 in the last ninety days. 16.36% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.